Opus Genetics (IRD) EBIT (2010 - 2026)
Opus Genetics (IRD) posted quarterly EBIT of -$14.4 million for Q1 2026, down 44.67% year-over-year from -$26.0 million in Q1 2025, and down 25.42% quarter-over-quarter from -$11.5 million in Q4 2025.
Opus Genetics (IRD) EBIT (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported EBIT for 17 consecutive years, with -$14.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 44.67% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$43.0 million (up 33.07% YoY), while the FY2025 annual figure was -$38.6 million, up 37.82% from the prior year.
- EBIT slipped to -$14.4 million in Q1 2026 per IRD's latest filing, from -$11.5 million in the prior quarter.
- Across five years, EBIT topped out at $34.2 million in Q4 2022 and bottomed at -$38.0 million in Q4 2024.
- Historically, EBIT has averaged -$6.3 million across 5 years, with a median of -$7.7 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT soared 656.26% — and 2024, when it sank 600.48%.
- Opus Genetics' EBIT stood at $34.2 million in 2022, then sank by 115.87% to -$5.4 million in 2023, then tumbled by 600.48% to -$38.0 million in 2024, then jumped by 69.88% to -$11.5 million in 2025, then retreated by 25.42% to -$14.4 million in 2026.
- Business Quant data shows IRD's EBIT at -$14.4 million in Q1 2026, -$11.5 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -16.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.48 Mn |
| Mar 31, 2026 | -14.36 Mn |
| Dec 31, 2025 | -11.45 Mn |
| Sep 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -9.93 Mn |
| Dec 31, 2024 | -38.03 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -7.71 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | -5.39 Mn |
| Mar 31, 2023 | -6.13 Mn |
| Dec 31, 2022 | 34.21 Mn |
| Sep 30, 2022 | -4.54 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -4.23 Mn |